Single doses
SAD
Part A of the study was a single ascending dose (SAD) study conducted in seven dosed cohorts. Each cohort was composed of eight participants, and in each cohort, participants were randomized to receive dersimelagon suspension (n = 6) or placebo suspension (n = 2). In total, 56 participants were included and received dersimelagon at doses of 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, and 600 mg. In parts D, F, and H of the study, participants received a single oral dose of either 100 mg of dersimelagon (n = 6) or placebo (n = 2) as a tablet formulation. To evaluate the effect of sex difference Part D included eight female participants, and Part F evaluated the effect of race, and included eight Black participants. Part H evaluated the effect of age in eight participants aged ≥ 65 years.